메뉴 건너뛰기




Volumn 58, Issue , 2014, Pages 48-54

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

Author keywords

Bone mineral density; Bone turnover markers; Denosumab; Postmenopausal osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; RISEDRONIC ACID;

EID: 84886797240     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.10.006     Document Type: Article
Times cited : (134)

References (19)
  • 1
    • 0032510309 scopus 로고    scopus 로고
    • Treatment of postmenopausal osteoporosis
    • Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998, 338:736-746.
    • (1998) N Engl J Med , vol.338 , pp. 736-746
    • Eastell, R.1
  • 2
    • 22044443714 scopus 로고    scopus 로고
    • Clinical practice. Screening for osteoporosis
    • Raisz L.G. Clinical practice. Screening for osteoporosis. N Engl J Med 2005, 353:164-171.
    • (2005) N Engl J Med , vol.353 , pp. 164-171
    • Raisz, L.G.1
  • 3
    • 0034719619 scopus 로고    scopus 로고
    • Osteoporosis prevention, diagnosis, and therapy
    • [cited 2013, May 28, Available at ]M 27_#2013;29
    • Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement March 27-29 2000, 17:1-36. [cited 2013, May 28, Available at http://consensus.nih.gov/2000/2000Osteoporosis111html.htm].
    • (2000) NIH Consens Statement , vol.17 , pp. 1-36
  • 4
    • 33744992495 scopus 로고    scopus 로고
    • Osteoporosis
    • Sambrook P., Cooper C. Osteoporosis. Lancet 2006, 367:2010-2018.
    • (2006) Lancet , vol.367 , pp. 2010-2018
    • Sambrook, P.1    Cooper, C.2
  • 5
    • 21344464904 scopus 로고    scopus 로고
    • Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women
    • Recker R.R., Gallagher R., MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005, 80:856-861.
    • (2005) Mayo Clin Proc , vol.80 , pp. 856-861
    • Recker, R.R.1    Gallagher, R.2    MacCosbe, P.E.3
  • 6
    • 33746821808 scopus 로고    scopus 로고
    • Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases
    • Siris E.S., Harris S.T., Rosen C.J., Barr C.E., Arvesen J.N., Abbott T.A., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013-1022.
    • (2006) Mayo Clin Proc , vol.81 , pp. 1013-1022
    • Siris, E.S.1    Harris, S.T.2    Rosen, C.J.3    Barr, C.E.4    Arvesen, J.N.5    Abbott, T.A.6
  • 7
    • 0037673945 scopus 로고    scopus 로고
    • Osteoclast differentiation and activation
    • Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
    • (2003) Nature , vol.423 , pp. 337-342
    • Boyle, W.J.1    Simonet, W.S.2    Lacey, D.L.3
  • 9
    • 58149099647 scopus 로고    scopus 로고
    • Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial
    • Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio L.H., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
    • (2009) J Bone Miner Res , vol.24 , pp. 153-161
    • Brown, J.P.1    Prince, R.L.2    Deal, C.3    Recker, R.R.4    Kiel, D.P.5    de Gregorio, L.H.6
  • 10
    • 77953454405 scopus 로고    scopus 로고
    • Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
    • Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
    • (2010) J Bone Miner Res , vol.25 , pp. 72-81
    • Kendler, D.L.1    Roux, C.2    Benhamou, C.L.3    Brown, J.P.4    Lillestol, M.5    Siddhanti, S.6
  • 11
    • 84886773001 scopus 로고    scopus 로고
    • Psychometric properties of the Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) in postmenopausal women with osteoporosis (OP) treated with bisphosphonates (BP)
    • Reynolds K., Viswanathan H., O'Malley C., Muntner P., Harrison T., Cheetham T.C., et al. Psychometric properties of the Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) in postmenopausal women with osteoporosis (OP) treated with bisphosphonates (BP). J Bone Miner Res 2011, 24:S367.
    • (2011) J Bone Miner Res , vol.24
    • Reynolds, K.1    Viswanathan, H.2    O'Malley, C.3    Muntner, P.4    Harrison, T.5    Cheetham, T.C.6
  • 12
    • 0022072706 scopus 로고
    • Testing for qualitative interactions between treatment effects and patient subsets
    • Gail M., Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985, 41:361-372.
    • (1985) Biometrics , vol.41 , pp. 361-372
    • Gail, M.1    Simon, R.2
  • 13
    • 78349249359 scopus 로고    scopus 로고
    • Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research
    • Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
    • (2010) J Bone Miner Res , vol.25 , pp. 2267-2294
    • Shane, E.1    Burr, D.2    Ebeling, P.R.3    Abrahamsen, B.4    Adler, R.A.5    Brown, T.D.6
  • 16
    • 79951689707 scopus 로고    scopus 로고
    • Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial
    • Miller P.D., Wagman R.B., Peacock M., Lewiecki E.M., Bolognese M.A., Weinstein R.L., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011, 96:394-402.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 394-402
    • Miller, P.D.1    Wagman, R.B.2    Peacock, M.3    Lewiecki, E.M.4    Bolognese, M.A.5    Weinstein, R.L.6
  • 17
    • 34250165747 scopus 로고    scopus 로고
    • Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
    • McClung M., Recker R., Miller P., Fiske D., Minkoff J., Kriegman A., et al. Intravenous zoledronic acid 5mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007, 41:122-128.
    • (2007) Bone , vol.41 , pp. 122-128
    • McClung, M.1    Recker, R.2    Miller, P.3    Fiske, D.4    Minkoff, J.5    Kriegman, A.6
  • 18
    • 84879122105 scopus 로고    scopus 로고
    • Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial
    • Recknor C., Czerwinski E., Bone H.G., Bonnick S.L., Binkley N., Palacios S., et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 2013, 121:1291-1299.
    • (2013) Obstet Gynecol , vol.121 , pp. 1291-1299
    • Recknor, C.1    Czerwinski, E.2    Bone, H.G.3    Bonnick, S.L.4    Binkley, N.5    Palacios, S.6
  • 19
    • 84863116878 scopus 로고    scopus 로고
    • Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
    • Austin M., Yang Y.C., Vittinghoff E., Adami S., Boonen S., Bauer D.C., et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 2012, 27:687-693.
    • (2012) J Bone Miner Res , vol.27 , pp. 687-693
    • Austin, M.1    Yang, Y.C.2    Vittinghoff, E.3    Adami, S.4    Boonen, S.5    Bauer, D.C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.